Natco pushes ahead with bid to compulsorily licence anti-cancer drug from Bayer
Natco Pharma, an Indian generic pharmaceutical company, has lodged an application with the Indian Patent Office requesting the grant of a compulsory licence to produce a generic version of Bayer’s anti-cancer drug Nexavar. If granted, this would be the first-ever compulsory licence issued by the Indian Patent Office and would set the bar for future applicants.